New shot for tough esophageal cancer enters early human testing
NCT ID NCT07203898
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called IPM514 in 36 people with advanced esophageal cancer that cannot be removed by surgery or has spread. The drug is given as a shot, and the main goals are to check safety and find the best dose. Researchers will also look for early signs that the drug is shrinking tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- AI biomarker may reveal who responds to esophageal cancer immunotherapy
- Can a single Protein's mutations predict esophageal cancer outcomes?
- A sponge you swallow could detect esophageal cancer before it spreads